Ki-67 proliferation index (IHC, % positive nuclei)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-KI67-PROLIFERATION-INDEX |
|---|---|
| Type | Biomarker |
| Aliases | Ki-67Ki-67 proliferation indexKi-67 індекс проліферації (ІГХ, % позитивних ядер)MIB-1proliferation index |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy (Ki-67 / MIB-1 antibody); count nuclear-positive cells in hot-spot Unitspercentage (0-100% positive nuclei) |
| Related biomarkers | None declared |
Notes
Universal proliferation marker across hematologic + solid neoplasms: - **Burkitt** (~100% — defining): highest Ki-67 of any human malignancy - **HGBL** (~80-100%) - **DLBCL** (~60-80%): higher Ki-67 may identify "double-expressor" aggressive subset - **MCL** (~10-50% — defines MIPI-b): >30% = blastoid-like aggressive, triggers RF-MCL-BLASTOID-OR-TP53 → BTKi-R route - **FL** grade: 1-2 typically <30%; grade 3 ≥30% (informs grade) - **Indolent NHL** (CLL, MZL, indolent FL): typically <20% - **Plasma cell myeloma**: >40-60% may indicate plasma cell leukemia transformation Algorithm-impacting in MCL (drives BTKi-R via blastoid RedFlag at >30%). Informational/grading elsewhere.
Used By
Red flag
RF-MCL-BLASTOID-OR-TP53- Mantle cell lymphoma with blastoid / pleomorphic morphology OR TP53 mutation OR del(17p)...